And page 13
Patients treated with DEP® docetaxel have exhibited:
"No neutropenia (docetaxel dose limiting toxicity)
No alopecia (hair loss) reported
No hypersensitivity
No standard steroid pre-treatment required
Encouraging efficacy signals in a significant proportion of patients including:
in pancreatic (SD*>20 wks), oesophageal (SD >18 wks), prostate, lung, H&N and brain tumours
at low doses, in cancers not responsive to docetaxel and in a heavily pre-treated patient cohort"
Well, I think we have a draft of phase 1 DEP DOX
And page 13 Patients treated with DEP® docetaxel have exhibited:...
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
